Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (99)
Australian public assessment report (AusPar) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (11)
2015 (8)
2014 (8)
2013 (14)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1994 (1)
1993 (3)
1991 (2)

Search

Sponsor content

225 result(s) found, displaying 81 to 90

MPL-HYDROMORPHONE hydromorphone hydrochloride 4mg tablet bottle Cancelled under Section 30(1)(c) of the Act

29 October 2021

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-HYDROMORPHONE hydromorphone hydrochloride 2 mg tablet bottle Cancelled under Section 30(1)(c) of the Act

29 October 2021

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
NYXOID naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial (309381)

18 September 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for NYXOID naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial.
MPL-BUPRENORPHINE/NALOXONE 0.7/0.18 buprenorphine (as HCl) 0.7 mg / naloxone (as HCl dihydrate) 0.18 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 1.4/0.36 buprenorphine (as HCl) 1.4 mg / naloxone (as HCl dihydrate) 0.36 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 2.9/0.71 buprenorphine (as HCl) 2.9 mg / naloxone (as HCl dihydrate) 0.71 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 5.7/1.4 buprenorphine (as HCl) 5.7 mg / naloxone (as HCl dihydrate) 1.4 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 8.6/2.1 buprenorphine (as HCl) 8.6 mg / naloxone (as HCl dihydrate) 2.1 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BUPRENORPHINE/NALOXONE 11.4/2.9 buprenorphine (as HCl) 11.4 mg / naloxone (as HCl dihydrate) 2.9 mg sublingual tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 November 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
AusPAR: Pralatrexate

17 November 2020

Australian public assessment report (AusPar)

Australian Public Assessment Report for Pralatrexate

Pages

First page
Previous page
…
Page 5
Page 6
Page 7
Page 8
Current page 9
Page 10
Page 11
Page 12
Page 13
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.